Quantum Flex: Where Cells Thrive

Introducing the Next Generation of Cell Expansion – Arriving Fall 2022

Are you ready for the next generation of cell expansion? Automate the right way, right from the start with the Quantum Flex platform. Gain the flexibility, scalability and connectivity to grow with your therapy, from process development to clinical manufacturing.

  • Flexibility: Automated expansion of a variety of applications — suspension and adherent cells, as well as viral vector and exosome production.
  • Scalability: Meet early process development and small batch needs with our newly introduced smaller bioreactor, then scale up to a standard size for larger batch manufacturing — all in the same compact, automated, functionally closed system.
  • Advanced software tools: Gain visibility and process control, including remote monitoring, fleet management and user access capabilities, with the Cell Processing Application.
  • High yields in a concentrated harvest volume: Achieve billions of suspension cells and hundreds of millions of adherent cells, always harvested in a volume < 1 L for simplified post-harvest processing.1,2
  • Minimal seeding requirements: Free yourself from manual preculture — seed the Quantum bioreactor with small amounts of starting material (< 30 million T cells or < 5 million MSCs).3,4,5,6*
  • High viability and stable phenotypes: Count on high product viability — typically > 90% — while maintaining stable cell phenotypes.3,4,5,6
  • cGMP and 21 CFR Part 11/Annex 11 compliance: Ease your mind with a system, including the newly introduced Cell Processing Application 3.0, that facilitates compliance with current Good Manufacturing Practices and 21 CFR Part 11/Annex 11 regulations and provides a fully non-DEHP fluid path.

Summary Sheet

Quantum Flex at a Glance

Download a summary of Quantum Flex information.


Simplify With Quantum Flex

The Quantum Flex platform facilitates lower seeding densities and reduces the need for manual preculture.1,2,3 A second bioreactor option (~1/10th the size) provides a scaled-down model ideal for process development and research, reducing time, risk and cost.

See the difference for suspension and adherent cells and small clinical batches in this infographic.

Connect with a representative today.

Stay updated

Sign me up for updates about Quantum Flex

Fields marked * are required


Sales & Marketing Required Field
Sales & Marketing Required Field
Sales & Marketing Required Field
Use Master Country Picklist from SFDC: Sales & Marketing Field
Use Master Picklist "Industry" from SFDC: Sales & Marketing Field
Use Master Picklist "Department" from SFDC: Sales & Marketing Field
Sales & Marketing Required Field
Sales & Marketing Required Field
Use Product Family SFDC Picklist
Use SFDC Business Picklist
Sales & Marketing Required Field


Optin for Eloqua Email Marketing Communication. ON UNLESS INSTRUCTED OTHERWISE.
Optin for Sales Contact - Passes to SFDC. OFF UNLESS INSTRUCTED OTHERWISE.
Sales & Marketing Optional Field
Sales and Marketing Optional Field
Sales and Marketing Optional Field


Triggers Task Priority - Task Type SFDC Picklist
Match Call to Action with Form Asset
Use Lead Source SFDC Picklist.
Always NEW
SFDC Campaign ID from SFDC Campaign URL


Provide name of campaign or event if applicable
Global Business Area Q1 Text
Global Business Area Answers to Q1
Global Business Area Q2 Text
Global Business Area Answers to Q2
Global Business Area Q3 Text
Global Business Area Answers to Q3

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today.

It is the responsibility of the user to validate the safety and efficacy of the expanded cells for their intended application. Performance varies by user and is dependent on customer processes and materials.
* Seeding and yield numbers provided are for the large sized bioreactor.

1Data on file at Terumo Blood and Cell Technologies.
2Hanley PJ, Mei Z, Durett AG, et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy. 2014;16(8):1048-1058.
3Nankervis B, Jones M, Vang B, Rice Jr BR, Coeshott C, Beltzer J. Optimizing T cell expansion in a hollow-fiber bioreactor. Curr Stem Cell Rep. 2018;4(1):46-51.
4Jones M, Nankervis B, Roballo KS, Pham H, Bushman J, Coeshott C. A comparison of automated perfusion- and manual diffusion-based human regulatory T cell expansion and functionality using a soluble activator complex. Cell Transplant. 2020;29:963689720923578.
5Coeshott C, Vang B, Jones M, Nankervis B. Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System. J Transl Med. 2019;17:258.
6Williams AM, Dennahy IS, Bhatti UF, et al. Mesenchymal stem cell-derived exosomes provide neuroprotection and improve long-term neurologic outcomes in a swine model of traumatic brain injury and hemorrhagic shock. J Neurotrauma. 2019;36(1):54-60.